CRISPR Therapeutics Posts $12.7M in Q3 Revenue
CRSP is trading near its 52-week low of $44.12 (11% above the low).
Summary
CRISPR Therapeutics reported third-quarter revenue of $12.7M, while CASGEVY revenue came in at $99M, up 30% quarter over quarter. The company entered the quarter with a $2.36B cash position and a narrower net loss, giving it plenty of runway regardless of the revenue swing. Revenue here is lumpy and tied to CASGEVY shipments and collaboration items, so the headline number alone doesn't settle the quarter — watch the full release for the loss per share, cash burn, and any CASGEVY volume detail. This is the first hard Q3 number; the rest of the P&L follows.
At the time of this announcement, CRSP was trading at $49.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $44.12 to $65.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.